• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Connect Biopharma Holdings Limited (Amendment)

    2/13/24 4:27:33 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTB alert in real time by email
    SC 13G/A 1 biofortune13ga20231231-fina.htm SC 13G/A Document


     


    Securities and Exchange Commission
    Washington, D.C. 20549

    ——————————————

    Schedule 13G
    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant
    to § 240.13d-1(b), (c) and (d) and Amendments Thereto
    Filed Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)*

    ——————————————

    Connect Biopharma Holdings Limited
    (Name of Issuer)


    Ordinary shares, par value $0.000174 per share
    (Title of Class of Securities)


    207523101**
    (CUSIP Number)


    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    ——————————————

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

    *    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **    There is no CUSIP number assigned to the Ordinary Shares of the Issuer (“Ordinary Shares”). CUSIP number 207523101 has been assigned to the American Depositary Shares of the Issuer (“ADSs”). Each ADS represents one Ordinary Share.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



     





    CUSIP No. 207523101Schedule 13G
    Page 1 of 6





    1
    Names of Reporting Persons

    BioFortune Inc.
    2
    Check the Appropriate Box if a Member of a Group
    (a) ☐    (b) ☐
    3SEC Use Only
    4
    Citizenship or Place of Organization

    British Virgin Islands
    Number of Shares
    Beneficially Owned by Each Reporting
    Person With
    5
    Sole Voting Power

    0
    6
    Shared Voting Power

    6,158,016
    7
    Sole Dispositive Power

    0
    8
    Shared Dispositive Power

    6,158,016
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,158,016
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    Not Applicable
    11
    Percent of Class Represented by Amount in Row 9

    11.2%
    12
    Type of Reporting Person

    CO





    CUSIP No. 207523101Schedule 13G
    Page 2 of 6





    1
    Names of Reporting Persons

    Wubin Pan
    2
    Check the Appropriate Box if a Member of a Group
    (a) ☐    (b) ☐
    3SEC Use Only
    4
    Citizenship or Place of Organization

    Canada
    Number of Shares
    Beneficially Owned by Each Reporting
    Person With
    5
    Sole Voting Power

    530,894
    6
    Shared Voting Power

    6,728,292
    7
    Sole Dispositive Power

    530,894
    8
    Shared Dispositive Power

    6,728,292
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,728,292
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    Not Applicable
    11
    Percent of Class Represented by Amount in Row 9

    12.1%
    12
    Type of Reporting Person

    IN




    CUSIP No. 207523101Schedule 13G
    Page 3 of 6



    ITEM 1. (a) Name of Issuer:

    Connect Biopharma Holdings Limited (the "Issuer").

    (b) Address of Issuer’s Principal Executive Offices:

    12265 El Camino Real, Suite 350, San Diego CA 92130.


    ITEM 2. (a) Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:.

    BioFortune Inc.
    Wubin Pan


    (b) Address or Principal Business Office:

    The business address of the Reporting Persons is c/o BioFortune Inc., Coastal Building, Wickham’s Cay II, P. O. Box 2221, Road Town, Tortola, British Virgin Islands.

    (c) Citizenship of each Reporting Person is:

    BioFortune Inc. is organized under the laws of the British Virgin Islands. Wubin Pan is a citizen of Canada.

    (d) Title of Class of Securities:

    Ordinary Shares, par value $0.000174 per share. The Ordinary Shares are sold on the U.S. market as ADSs, each of which represents one Ordinary Share.

    (e) CUSIP Number:

    207523101


    ITEM 3.

    Not applicable.


    ITEM 4. Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Ordinary Shares as of December 31, 2023. The percentage calculation is based upon 55,102,954 Ordinary Shares outstanding as of December 31, 2023.




    CUSIP No. 207523101Schedule 13G
    Page 4 of 6



    Reporting Person
    Amount beneficially owned
    Percent of class:
    Sole power to vote or to direct the vote:
    Shared power to vote or to direct the vote:
    Sole power to dispose or to direct the disposition of:
    Shared power to dispose to direct the disposition of:
    BioFortune Inc.6,158,01611.2%06,158,01606,158,016
    Wubin Pan6,728,29212.1%530,8946,728,292530,8946,728,292


    Mr. Pan is the beneficial owner of 6,728,292 Ordinary Shares, which consists of (i) 6,158,016 Ordinary Shares held of record by BioFortune Inc.; (ii) 530,894 Ordinary Shares underlying stock options held of record by Mr. Pan that are exercisable as of March 1, 2024; and (iii) 39,382 Ordinary Shares held of record by Mr. Pan’s spouse. Mr. Pan is the sole shareholder of BioFortune Inc. As a result, Mr. Pan may be deemed to share beneficial ownership over the securities held of record by BioFortune Inc.


    ITEM 5. Ownership of Five Percent or Less of a Class.

    Not applicable.


    ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.


    ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.


    ITEM 8. Identification and Classification of Members of the Group.

    Not applicable.


    ITEM 9. Notice of Dissolution of Group.

    Not applicable.


    ITEM 10. Certification.

    Not applicable.



    CUSIP No. 207523101Schedule 13G
    Page 5 of 6



    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 13, 2024



    BioFortune Inc.

    By:    /s/ Wubin Pan    

    Name:    Wubin Pan

    Title:    Director


    Wubin Pan

    /s/ Wubin Pan    




    CUSIP No. 207523101Schedule 13G
    Page 6 of 6

    LIST OF EXHIBITS


    Exhibit No.Description
    99
    Joint Filing Agreement


    Get the next $CNTB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNTB

    DatePrice TargetRatingAnalyst
    6/12/2025$7.00Buy
    H.C. Wainwright
    3/4/2024$7.00Buy
    H.C. Wainwright
    More analyst ratings

    $CNTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Connect Biopharma with a new price target

    H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00

    6/12/25 7:54:22 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Connect Biopharma with a new price target

    H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00

    3/4/24 7:36:11 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

    Company and Former Cincinnati Bengals Running Back Known for the "Ickey Shuffle" Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company) and the Jovante Woods Foundation (the Foundation) today kicked off a collaboration to expand the Foundation's asthma education program across the U.S. On this day in 2010, former Cincinnati Bengals running back Elbert "Ickey" Woods lost his 16-year-old son, Jovante, to an acute asthma attack he suffered on his way home from high school football practice. Ickey an

    8/14/25 8:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

    – Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the potential of rademikibart to deliver differentiated efficacy and safety in patients with eosinophilic-driven type 2 asthma and COPD – – New drug application for rademikibart for the treatment of AD submitted to China's NMPA by Simcere, the Company's exclusive licensee in Greater China – – Announced plans to terminate ADR program and directly list ordinary shares on Nasdaq to better facilitate institutional visibility, eliminate ADR depositary fees, and strengthen ability to expand investor b

    8/13/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

    – Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. "We are pleased to welcome Jim to our Board of Directors," sai

    7/22/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Leadership Updates

    Live Leadership Updates

    View All

    Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

    – Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. "We are pleased to welcome Jim to our Board of Directors," sai

    7/22/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Attovia Therapeutics Appoints Chief Financial Officer

    FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ:CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory diseases. At Attovia, Mr. Chan will lead the company's finance and operations functions and serve on its Executive Committee, reporting to Tao Fu, Chief Executive Officer. "I am delighted to welcome Steve to Attovia at this critical growth period for the company. He brings over thirt

    10/15/24 7:30:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

    Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect's new management is currently evaluating the future clinical development strategy for rademikibartAs part of Connect's transformation into a U.S.-centric company, the Company will be significantly reducing its presence in ChinaCash and cash equivalents of $110.2 million expected to support planned operations into at least the first half of 2027 SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a U.S.-headquartered global clinical-stage bio

    9/5/24 4:05:00 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Financials

    Live finance-specific insights

    View All

    Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

    The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibartSignificant improvement in asthma control occurred early and was sustained through Week 24 for both doses of rademikibartSafety results suggest rademikibart was generally well toleratedA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:

    12/12/23 6:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

    SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to d

    12/11/23 4:05:21 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

    Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 Over 36 weeks of treatment in Stage 2 of the study, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increaseRademikibart continued to be well tolerated over 52 weeks of treatmentA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings L

    11/21/23 6:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    SEC Filings

    View All

    SEC Form 10-Q filed by Connect Biopharma Holdings Limited

    10-Q - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    8/13/25 9:04:38 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Holdings Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    8/13/25 9:03:26 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Holdings Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    7/22/25 9:07:04 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    7/1/24 4:16:48 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/27/24 9:00:28 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/27/24 4:19:26 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care